{"schema_version":"secwatch.filing_event.v1","accession":"0001193805-26-000516","form_type":"8-K","ticker":"IMUX","cik":"0001280776","company_name":"IMMUNIC, INC.","filed_at":"2026-04-28T23:59:59+00:00","discovered_at":"2026-05-14T18:02:32.084356+00:00","generated_at":"2026-05-15T02:44:40.206813+00:00","sec_items":["5.02","7.01","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Immunic appoints Michael Panzara as CMO; prior CMO Andreas Muehler resigns, transitions to consultant","bullets":["Michael Panzara appointed CMO effective April 24, 2026; base salary $600K, annual bonus target ≥50% of salary, signing bonus $125K.","Andreas Muehler resigned as CMO effective April 27, 2026; will serve as Senior Medical Officer through April 30, then consultant 10 months at $10K/month.","Panzara granted inducement option for 300K shares (post-split) vesting 50% at 1 year, 50% over 24 months thereafter.","Muehler receives 12 months base salary severance, pro-rated FY2026 bonus, full equity vesting, and 3-year post-termination exercise window.","No disagreement cited for Muehler's departure; Panzara brings >25 years neurology drug development experience including MS approvals at Biogen/Sanofi."],"urls":{"canonical":"https://secwatch.observer/filing/0001193805-26-000516","json":"https://secwatch.observer/filing/0001193805-26-000516.json","markdown":"https://secwatch.observer/filing/0001193805-26-000516.md","text":"https://secwatch.observer/filing/0001193805-26-000516.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1280776/000119380526000516/0001193805-26-000516-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1280776/000119380526000516/e665394_8k-immunic.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T02:44:40.206813+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"f2b9f23105","claim":"Michael A. Panzara was appointed as Chief Medical Officer at IMMUNIC, INC..","evidence_excerpt":"Immunic, Inc. (the \"Company\") appointed Michael A. Panzara, M.D., M.P.H., as Chief Medical Officer of the Company, effective immediately.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1280776/000119380526000516/0001193805-26-000516-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Chief Medical Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}